HU192990B - Process for producing new compositions for injection containing 1-/2-hydroxy-ethyl/-2-methyl-5-nitro-imidazol - Google Patents
Process for producing new compositions for injection containing 1-/2-hydroxy-ethyl/-2-methyl-5-nitro-imidazol Download PDFInfo
- Publication number
- HU192990B HU192990B HU843127A HU312784A HU192990B HU 192990 B HU192990 B HU 192990B HU 843127 A HU843127 A HU 843127A HU 312784 A HU312784 A HU 312784A HU 192990 B HU192990 B HU 192990B
- Authority
- HU
- Hungary
- Prior art keywords
- particle size
- methyl
- metronidazole
- maximum particle
- hydroxyethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 12
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 title claims 2
- 238000002347 injection Methods 0.000 title description 23
- 239000007924 injection Substances 0.000 title description 23
- 239000000203 mixture Substances 0.000 title description 5
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 title 1
- 239000002245 particle Substances 0.000 claims abstract description 65
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 57
- 230000007935 neutral effect Effects 0.000 claims abstract description 11
- 229940102213 injectable suspension Drugs 0.000 claims abstract 3
- 239000000725 suspension Substances 0.000 claims description 33
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000375 suspending agent Substances 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 7
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- -1 1- (2-hydroxyethyl) ethyl Chemical group 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229940086737 allyl sucrose Drugs 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical class CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 abstract description 51
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000007900 aqueous suspension Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- DUVVGYBLYHSFMV-YGEZULPYSA-N 4-methyl-n-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]benzamide Chemical compound C1=CC(C)=CC=C1C(=O)NC(=O)N[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DUVVGYBLYHSFMV-YGEZULPYSA-N 0.000 description 1
- 206010001981 Amoebic infections Diseases 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB838322364A GB8322364D0 (en) | 1983-08-19 | 1983-08-19 | Compositions of matter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT35650A HUT35650A (en) | 1985-07-29 |
| HU192990B true HU192990B (en) | 1987-08-28 |
Family
ID=10547557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU843127A HU192990B (en) | 1983-08-19 | 1984-08-17 | Process for producing new compositions for injection containing 1-/2-hydroxy-ethyl/-2-methyl-5-nitro-imidazol |
Country Status (17)
| Country | Link |
|---|---|
| JP (1) | JPS6067468A (da) |
| AU (1) | AU577055B2 (da) |
| BE (1) | BE900381A (da) |
| CA (1) | CA1214727A (da) |
| CH (1) | CH662812A5 (da) |
| DE (1) | DE3430354A1 (da) |
| DK (1) | DK165817C (da) |
| FR (1) | FR2560043B1 (da) |
| GB (2) | GB8322364D0 (da) |
| HU (1) | HU192990B (da) |
| IL (1) | IL72714A (da) |
| IT (1) | IT1213208B (da) |
| LU (1) | LU85511A1 (da) |
| NL (1) | NL8402510A (da) |
| NZ (1) | NZ209270A (da) |
| SE (1) | SE460095B (da) |
| ZA (1) | ZA846431B (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL194638C (nl) * | 1986-12-19 | 2002-10-04 | Novartis Ag | Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat. |
| US7849856B2 (en) | 2001-06-25 | 2010-12-14 | 3M Innovative Properties Company | Respirator valve |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB213928A (en) * | 1923-04-06 | 1925-07-02 | Deutsche Werke Ag | Improvements in or relating to compensated induction motors for single or polyphase alternating current |
| US3457348A (en) * | 1966-06-27 | 1969-07-22 | American Cyanamid Co | Stable syringeable suspensions of parenteral drugs in complex floc form |
| GB1430411A (en) * | 1973-04-05 | 1976-03-31 | May & Baker Ltd | Method and compositions for combating swine dysentery |
| US4029782A (en) * | 1975-04-28 | 1977-06-14 | Eli Lilly And Company | Cefazolin suspension for parenteral administration |
| GB2000025A (en) * | 1977-05-14 | 1979-01-04 | Pfizer Ltd | Nitroimidazole formulations |
| DE2932691A1 (de) * | 1979-08-11 | 1981-04-09 | Bayer Ag, 5090 Leverkusen | Antimykotische mittel mit hoeherer freisetzung der wirkstoffe |
-
1983
- 1983-08-19 GB GB838322364A patent/GB8322364D0/en active Pending
-
1984
- 1984-08-13 IT IT8422323A patent/IT1213208B/it active
- 1984-08-15 NL NL8402510A patent/NL8402510A/nl not_active Application Discontinuation
- 1984-08-16 FR FR8412854A patent/FR2560043B1/fr not_active Expired
- 1984-08-17 DK DK397084A patent/DK165817C/da not_active IP Right Cessation
- 1984-08-17 IL IL72714A patent/IL72714A/xx unknown
- 1984-08-17 GB GB08420959A patent/GB2145088B/en not_active Expired
- 1984-08-17 LU LU85511A patent/LU85511A1/fr unknown
- 1984-08-17 CA CA000461262A patent/CA1214727A/en not_active Expired
- 1984-08-17 SE SE8404130A patent/SE460095B/sv not_active IP Right Cessation
- 1984-08-17 NZ NZ209270A patent/NZ209270A/en unknown
- 1984-08-17 AU AU32022/84A patent/AU577055B2/en not_active Ceased
- 1984-08-17 ZA ZA846431A patent/ZA846431B/xx unknown
- 1984-08-17 CH CH3960/84A patent/CH662812A5/fr not_active IP Right Cessation
- 1984-08-17 BE BE0/213510A patent/BE900381A/fr not_active IP Right Cessation
- 1984-08-17 DE DE19843430354 patent/DE3430354A1/de not_active Ceased
- 1984-08-17 HU HU843127A patent/HU192990B/hu not_active IP Right Cessation
- 1984-08-17 JP JP59170517A patent/JPS6067468A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK397084A (da) | 1985-02-20 |
| GB2145088B (en) | 1986-10-08 |
| NL8402510A (nl) | 1985-03-18 |
| AU3202284A (en) | 1985-02-21 |
| JPS6067468A (ja) | 1985-04-17 |
| CA1214727A (en) | 1986-12-02 |
| IL72714A (en) | 1988-09-30 |
| DK165817B (da) | 1993-01-25 |
| HUT35650A (en) | 1985-07-29 |
| GB8420959D0 (en) | 1984-09-19 |
| SE8404130L (sv) | 1985-02-20 |
| BE900381A (fr) | 1985-02-18 |
| FR2560043A1 (fr) | 1985-08-30 |
| FR2560043B1 (fr) | 1988-08-05 |
| SE8404130D0 (sv) | 1984-08-17 |
| GB8322364D0 (en) | 1983-09-21 |
| DE3430354A1 (de) | 1985-03-07 |
| IT1213208B (it) | 1989-12-14 |
| LU85511A1 (fr) | 1985-04-24 |
| GB2145088A (en) | 1985-03-20 |
| SE460095B (sv) | 1989-09-11 |
| AU577055B2 (en) | 1988-09-15 |
| DK165817C (da) | 1993-06-21 |
| NZ209270A (en) | 1988-02-29 |
| DK397084D0 (da) | 1984-08-17 |
| CH662812A5 (fr) | 1987-10-30 |
| IT8422323A0 (it) | 1984-08-13 |
| ZA846431B (en) | 1985-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1468697B1 (en) | Compositions containing piperacillin and tazobactam useful for injection | |
| CA2326198C (en) | Cosolvent formulations | |
| AU2010325632A1 (en) | Process for preparing pharmaceutical ophthalmic compositions | |
| ZA200201904B (en) | Topical suspension formulations containing ciprofloxacin and dexamethasone. | |
| US20020147239A1 (en) | Esmolol formulation | |
| TWI544934B (zh) | 含有氟喹諾酮抗生素藥物之經改良藥學組成物 | |
| CA2745123A1 (en) | Pharmaceutical suspension | |
| DE60215129T2 (de) | Esmolol-enthaltende zubereitungen | |
| US4038389A (en) | Medroxyprogesterone acetate compositions | |
| HU192990B (en) | Process for producing new compositions for injection containing 1-/2-hydroxy-ethyl/-2-methyl-5-nitro-imidazol | |
| WO2020136466A1 (en) | An injectable skeletal muscle relaxant and nsaid and method of making the same | |
| CN104244983A (zh) | 控制释放组合物及其使用方法 | |
| US10463674B2 (en) | Process for manufacturing sterile ophthalmic pharmaceutical suspensions | |
| JP6279395B2 (ja) | ブリンゾラミド懸濁性点眼液組成物の製造方法 | |
| US4029782A (en) | Cefazolin suspension for parenteral administration | |
| US9820991B2 (en) | Pharmaceutical composition comprising brinzolamide | |
| KR0169711B1 (ko) | 수의학적 조성물 | |
| CA2022513A1 (en) | Formulations of phenytoin sodium for intravenous administration | |
| RU2632708C1 (ru) | Способ получения комбинированного антибактериального препарата | |
| BR112014031083B1 (pt) | Composição farmacêutica veterinária não aquosa injetável, seringa contendo a referida composição e método de fabricação da mesma | |
| JP2026509786A (ja) | グラム陽性菌血症の治療に使用するチカグレロール静脈内製剤 | |
| EP1121933A1 (en) | Premixed alatrofloxacin injectable compositions | |
| JP2002544164A (ja) | ５−（２−クロロエチル）−４−メチルチアゾールエジシレート（クロメチアゾールエジシレート）の非経口処方物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HMM4 | Cancellation of final prot. due to non-payment of fee |